A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Kathleen Garrison
- Phone Number: 415-600-3126
- Email: garrisk@cpmcri.org
Study Contact Backup
- Name: Reshmi Pal
- Phone Number: 415-600-1652
- Email: palrx@cpmcri.org
Study Locations
-
-
California
-
Lafayette, California, United States, 94549
- Recruiting
- New Leaf Treatment Center
-
Contact:
- Kathleen Garrison
- Phone Number: 415-600-1652
- Email: garrisk@cpmcri.org
-
San Francisco, California, United States, 94107
- Not yet recruiting
- Addiction & Pharmacology Research Laboratory
-
Contact:
- Kathleen Garrison
- Phone Number: 415-600-1652
- Email: garrisk@cpmcri.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- English-speaking adults ≥ 18 years who are seeking treatment for MA addiction.
- Own a cellular phone with SMS text messaging capability and have an unlimited text messaging plan.
- Available to attend CBT therapy groups.
- Agreeable to conditions of the study and signed an informed consent form.
Exclusion Criteria:
- Projected to be unavailable > 12 hours/day to read and send text messages.
- Any medical or psychosocial condition that would preclude safe, useful, or consistent participation,
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CBT- based SMS text messaging intervention
cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention
|
Other Names:
|
|
Placebo Comparator: Placebo Texts
Placebo texts will be given instead of interventional texts
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of MA-negative urine samples between the 2-week CBT text period and the 2-week control period
Time Frame: 5 weeks
|
The primary efficacy measure for this study is the difference in proportion of MA-negative urine samples between the 2-week CBT text period and the 2-week control period.
Urine samples will be analyzed for MA by immunoassay with a cutoff of 1,000 ng/mL.
|
5 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gantt Galloway, PharmD, California Pacific Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2012.119-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amphetamine-Related Disorders
-
NCT06960265Not yet recruitingAmphetamine Use Disorders | rTMS Stimulation | NIRS | Amphetamine Dependence | rTMS | Amphetamine Abuse | Amphetamine Use Disorder
-
NCT01273701UnknownMethamphetamine Dependence | Methamphetamine Abuse | Amphetamine Dependence | Amphetamine Abuse
-
NCT04531384RecruitingAmphetamine Addiction
-
NCT01100853CompletedAmphetamine Dependence
-
NCT02285556CompletedAmphetamine Addiction
-
NCT02952196WithdrawnAmphetamine Addiction
-
NCT03221283CompletedAmphetamine Addiction
-
NCT00600145WithdrawnAmphetamine Dependence
Clinical Trials on CBT- based SMS text messaging intervention
-
NCT05997511Active, not recruitingCOVID-19 | Mental Health | Misinformation
-
NCT04379349CompletedPsychotic Disorders
-
NCT05509738TerminatedReminder Systems | Urinary Dysfunction | Text Messaging | Urinary Bladder | Behavior Change Techniques
-
NCT02627079CompletedA Diagnosis of Any Hematologic or Solid Malignancy
-
NCT01746758UnknownPregnancy | HIV | Contraception | Sexually Transmitted Infections
-
NCT03185741CompletedDiabetes Mellitus, Type 2 | Medication Adherence
-
NCT07070154Not yet recruitingIntervention | Control
-
NCT01433185CompletedHIV Infections | Acquired Immunodeficiency Syndrome
-
NCT01186575CompletedHIV Infections | Acquired Immunodeficiency Syndrome | Circumcision, Male | Patient Compliance | Cellular Phone
-
NCT02833246CompletedSarcoma | Lung | Solid Tumor Gastrointestinal